Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Siponimod-Intoleranz

Siponimod ist ein Arneimittel zur Behandlung von erwachsenen Patienten mit sekundär progredienter Multipler Sklerose. Laut Fachinformation sollte zusätzlich eine Krankheitsaktivität entweder durch die Beobachtung von Schüben oder mittels Bildgebung nachgewiesen sein. Die Dosierung ist streng von den vorhandenen CYP2C9-Varianten abhängig die vorher bestimmt werden müssen.

Gliederung

Störungen im Cytochrom P450-System
CYP1A2
CYP2A6
CYP2C9
CYP2D6
CYP3A4
CYP4F2
Siponimod-Intoleranz
CYP2C9

Referenzen:

1.

Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

external link
2.

Novartis: Mayzent® (Siponimod) Informationen zur sicheren Anwendung

3.

Ross KA et al. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

external link
4.

Speed WC et al. (2009) Global variation in CYP2C8-CYP2C9 functional haplotypes.

external link
5.

Maekawa K et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.

external link
6.

None (2001) Racial differences in the response to drugs--pointers to genetic differences.

external link
7.

Sullivan-Klose TH et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

external link
8.

Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

external link
9.

Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.

external link
10.

Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

external link
11.

Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

external link
12.

King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

external link
13.

Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

external link
14.

Gough SM et al. (2003) Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1.

external link
15.

Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin.

external link
16.

Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

external link
17.

Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

external link
18.

Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response.

external link
19.

Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

external link
20.

Thum T et al. (2000) Gene expression in distinct regions of the heart.

external link
21.

Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

external link
22.

Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

external link
23.

et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.

external link
24.

Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

external link
25.

Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

external link
Update: 26. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz